Zevra Homepage.
icon news News
icon investors
icon careers Careers icon contact Contacts
< Medical Publications and Presentations

Mass Balance and Metabolic Pathway Following Oral Administration of [14C]-Serdexmethylphenidate, a Novel Prodrug of d-Methylphenidate

The American Professional Society of ADHD and Related Disorders (APSARD) 2022 Annual Conference - January 14-16, 2022
Download PDF
Download PDF
About Us
Our Mission & Vision The Zevra Story Leadership Board of Directors What We Do Partnering
Patients & Caregiver
Clinical Trials Expanded Access Policy Niemann-Pick Disease Type C Urea Cycle Disorders Vascular Ehlers-Danlos
Our Products
MIPLYFFA® OLPRUVA®
Our Pipeline
Pipeline Clinical Trials Publications & Presentations Medical Literature Medical Information Investigator-Initiated Studies
Careers
Culture Job Openings
Investors
Investor Relations Events & Presentations Stock Quote & Chart Press Releases Corporate Governance Financials Contact Email Alerts
Contact [email protected] 888.958.1253
Footer link Zevra Facebook
Footer link Zevra X twitter
Footer link Zevra linkedin
© 2026 Zevra Therapeutics.
All rights reserved.
|
 Privacy Policy
|
 Notice at Collection
|
 Your Privacy Choices
|
 Terms of Use